Why Is AURINIA PHARMACEUTIC Equity (AUPH) Stock Up Today?
By the Top Tier Newswire AI Desk · August 20, 2026 at 9:55 AM ET · reviewed against 7 wire stories
AURINIA PHARMACEUTIC Equity (AUPH) is up +9.31% in the latest session. Our newswire has captured 7 stories on AUPH across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AUPH stock surged 9.31% to $17.68 in a sharp intraday rally driven by the resolution of patent litigation with Teva Pharmaceuticals. The settlement secures exclusivity for Aurinia’s drug voclosporin until at least 2036 and affirms the validity of key patents. The agreement removes a near-term competitive threat and supports the company’s long-term revenue outlook.
What Happened
Aurinia Pharmaceuticals announced a settlement with Teva that prevents the generic version of its drug LUPKYNIS from entering the U.S. market until December 2036. The agreement resolves litigation over Teva’s application to market a generic version of voclosporin, a key revenue driver for Aurinia. The settlement also covers 7.9 mg capsules and confirms the strength of Aurinia’s patent portfolio. The news was filed with the SEC in an 8-K on August 19 and was widely reported in the financial press. The stock opened with a 1.4% gap up and climbed steadily through the morning, reaching a high of $17.80 before settling at $17.68.
What The Data Shows
The stock’s intraday performance reflects strong investor confidence, with volume reaching 0.4 million shares, or 30% of the 3-month average. AUPH is currently trading near its 52-week high of $19.25 and has printed seven fresh 52-week highs on the day. The CEO, Kevin Tang, has added to his position with $12.5 million in insider purchases over the last 90 days, signaling alignment with long-term shareholders. The company’s fundamentals remain strong, with a P/E of 7.0, revenue growth of 19.8% in the trailing twelve months, and a net margin of 100.8%.
What To Watch
Aurinia is set to report its full-year 2026 sales results in the coming months. Investors should monitor coverage breadth and any further developments in patent litigation, as well as the company’s ability to meet its $315 million to $325 million revenue guidance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AUPH · Aug 20 session (5-min) · +6.99% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 7 stories · 55/100 bullish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
23d agoMarketChameleonBULLISH 67General
Aurinia’s Patent Settlement with Teva Secures Voclosporin Exclusivity Until 2036
August 20, 2026
Aurinia Pharmaceuticals resolves patent litigation with Teva, protecting its key drug voclosporin in the U.S. until at least December 2036. The agreement enforces Aurinia’s patent rights and delays Teva’s generic entry for over twelve more years, providing market certainty while related lawsuits continue against additional competitors.
24d agoStocktwits NewsBULLISH 67General
AUPH Stock Rallies 6% After-Hours — Here’s Why
Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.
24d agoSeeking AlphaBULLISH 56General
Aurinia settles Lupkynis patent litigation with Teva
Teva can’t launch a generic Lupkynis until at least Dec. 7, 2036 under a settlement with Aurinia. Read more here.
24d agoMarketWatchBULLISH 56General
Aurinia Settles Patent Infringement Lawsuit With Teva
24d agoInvesting.com MarketsBEARISH 34General
Aurinia stock falls on Teva patent settlement for voclosporin
Aurinia stock falls on Teva patent settlement for voclosporin
Teva's U.S. marketing is contingent on FDA approval; the settlement covers 7.9 mg capsules, while Aurinia's other patent cases continue.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →